The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer
Adjustment of SCr when calculating the CBDCA dose did not compromise the DI of total CBDCA and may rather contribute to maintaining DI in patients receiving dd-TC.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Nobuyuki Takahashi (ORCID: https://orcid.org/0000-0002-8592-6528)
- Kanako Mamishin (ORCID: https://orcid.org/0009-0009-8954-9895)
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Toru Mukohara (ORCID: https://orcid.org/0000-0002-8573-418X)
- Misao Fukuda (ORCID: https://orcid.org/0009-0000-7720-3875)
- Kaede Baba
- Chikako Funasaka (ORCID: https://orcid.org/0000-0003-0585-4884)
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Chihiro Kondoh (ORCID: https://orcid.org/0000-0001-6189-4851)
- Akira Hirota (ORCID: https://orcid.org/0000-0003-3301-089X)
- Toshikatsu Kawasaki (ORCID: https://orcid.org/0000-0002-7697-5512)
- Ako Hosono
- Hiromichi Nakajima (ORCID: https://orcid.org/0000-0001-6401-4258)
- Takehiro Nakao
- Shu Kato
- Mao Uematsu
- Mai Shimura
Institutions
- National Cancer Center Hospital East (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1002/cam4.70804
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00